BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer by Goldie Y.L. Lui, Reid Shaw, Franz X. Schaub, Isabella N. Stork, Kay E. Gurley, Caroline Bridgwater, Robert L. Diaz, Rachele Rosati, Hallie A. Swan, Tan A. Ince, Thomas C. Harding, Vijayakrishna K. Gadi, Barbara A. Goff, Christopher J. Kemp, Elizabeth M. Swisher, Carla Grandori

Get full text